Tekmira Pharmaceuticals this week released data from an ongoing phase I clinical trial of its RNAi-based cancer drug TKM-PLK1, showing that the drug is safe and offering hints of efficacy.

Notably, two patients have received the drug for at least six months with no evidence of cumulative toxicity. Meantime, three patients achieved stable disease, including one patient with metastatic appendiceal carcinoid cancer, another with metastatic colorectal cancer, and a third with metastatic adrenocortical carcinoma, Tekmira said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Cell this week: biobank of colorectal cancer organoids, ancient wolf genome analysis, and more.

With cloud computing becoming more attractive to researchers, Nature News offers some tips on how to get going.

In a series of articles, medical journals debate the necessity of conflict-of-interest policies.

Irwin Rose, who won the 2004 Nobel Prize in Chemistry for his work on ubiquitin-mediated protein degradation, has died.